This means someone has tried taking antidepressant medicine, but it didn't work for them. They've tried at least two different kinds of medicine, or maybe even more. It's a type of depression that hasn't responded to standard treatments.
Every report comes from a Lived member, sent anonymously.
Have you tried Auvelity (Dextromethorphan / Bupropion) for Treatment-Resistant Depression?
Treatment-resistant depression is major depression that has not improved enough despite treatment. The most widely used definition, the one the US Food and Drug Administration (FDA) uses, is depression that has not responded adequately to at least two different antidepressants, each taken at a proper dose, for long enough and consistently, during the current episode. By that standard, an estimated 30% or more of people with depression meet the definition. The label describes a person's treatment history rather than a separate disease. The depression itself looks like other major depression: persistent low mood or loss of interest, along with changes in sleep, appetite, energy, concentration and self-worth. What sets it apart is that ordinary first steps have not brought relief, which often means a longer illness, more disruption to work and relationships, and a need for a more specialized plan. It does not mean that nothing will work.
There is no single reason depression resists treatment, and researchers have found very few factors that reliably predict who will not respond. Some contributors are about the treatment itself: a dose that was too low, a trial that was too short, or a medicine stopped early because of side effects. These situations are sometimes called pseudo-resistance, because the depression may respond once treatment is given properly. Other contributors are about the illness and the person's wider health. Depression that is really part of bipolar disorder, ongoing trauma-related symptoms, anxiety, sleep problems, alcohol or drug use, personality difficulties, and medical illness can all make depression harder to treat. Long or repeated episodes and continuing stress in daily life can also stand in the way. None of these factors means a person did something wrong, and none makes recovery impossible.
There is no blood test or scan that shows treatment-resistant depression. A clinician reaches the conclusion by reviewing the history carefully: which medicines were tried, at what doses, for how long, how consistently they were taken, and what effect and side effects they had. Many people who seem resistant turn out to have had treatment that was not given a full chance. The review also asks whether major depression is the right diagnosis. A history of high-energy or elevated-mood periods can point to bipolar disorder, which is treated differently. The clinician also looks for anxiety, trauma, substance use, sleep disorders and medical problems such as thyroid disease that can keep depression going. Questionnaires that rate depression symptoms are often used to measure severity and to track whether the next treatment is helping.
Treatment usually starts by fixing what may have held earlier treatment back, such as adjusting a dose, allowing enough time or treating a condition alongside the depression. Beyond that, there are several established options, and the choice depends on how severe and urgent the depression is, what has been tried, other health conditions, and personal preference. Medication strategies include switching to a different antidepressant, combining two antidepressants, or adding another medicine to the current one. Evidence for switching and combining is mixed, so these are often tried with clear goals for judging the result. Some antipsychotic medicines, such as aripiprazole (Abilify), used at lower doses as add-ons, can help people whose depression has partly improved; a combination capsule of olanzapine (an antipsychotic) and fluoxetine (an antidepressant) is FDA-approved for treatment-resistant depression. Weight gain and other metabolic effects are a main trade-off with this group of medicines. Esketamine nasal spray (Spravato), a medicine related to the anesthetic ketamine, is FDA-approved for adults with treatment-resistant depression and can work faster than standard antidepressants. Because it can cause drowsiness, a detached or dreamlike feeling, rises in blood pressure and slowed breathing, and because it can be misused, it is given only in certified clinics. Each dose is taken under supervision with at least two hours of monitoring afterward, and people should not drive until the next day after a restful sleep. Ketamine given by intravenous infusion has similar evidence of benefit, but it is not FDA-approved for depression and is offered off-label, so how it is given and monitored varies between clinics. Brain stimulation treatments are another major route. Repetitive transcranial magnetic stimulation (rTMS) uses a magnetic coil held against the head to stimulate mood-related brain areas. It does not need anesthesia; a standard course is daily sessions on weekdays for four to six weeks, and newer accelerated schedules compress treatment into about a week. Side effects are usually mild, such as scalp discomfort or headache. Electroconvulsive therapy (ECT) briefly induces seizure activity under general anesthesia, usually three times a week for six to twelve sessions. It is among the most effective options for severe treatment-resistant depression, especially when a fast response is needed, and often works within the first week, but it can cause memory loss, especially for events around the treatment period, which usually improves over the weeks to months after treatment ends, though some memories from around that time may not return. Vagus nerve stimulation, an implanted device, is reserved for adults with long-lasting depression after at least four other treatments, and its results have been mixed. Talk therapy, such as cognitive behavioral therapy, is not proven to work on its own in treatment-resistant depression but gives meaningful added relief when combined with medication.
Finding an effective treatment often takes several attempts and can stretch over months. In a large US study of people working through successive treatment steps, the researchers estimated that up to about two thirds could eventually reach remission (a return to feeling mostly well), but each later step helped fewer people, and those who needed more steps were more likely to relapse afterward. That pattern explains why clinicians often move to stronger options, such as esketamine or brain stimulation, rather than repeating similar medicines. Improvement is often partial before it is complete, and the goal is a full return to daily functioning, not just fewer symptoms. Once something works, continuing treatment matters: medicines are usually kept going, and people who respond to ECT or rTMS typically need ongoing medication or maintenance sessions to stay well. Practical steps such as keeping a symptom record, protecting sleep, limiting alcohol and staying connected with supportive people make each treatment easier to judge and sustain.
Ask for a fuller review of your treatment if depression has not clearly improved after two adequate antidepressant trials, if side effects keep you from taking treatment, or if improvement stalls partway. A psychiatrist or a specialized depression or brain stimulation program can help when ordinary steps have not worked. Contact your prescriber promptly if depression gets noticeably worse after starting or changing a treatment, or if you notice unusually high energy, racing thoughts or a much-reduced need for sleep, which can signal a switch toward mania and may mean the depression is part of bipolar disorder. If you have thoughts of suicide or harming yourself, call or text the 988 Suicide and Crisis Lifeline right away; if you are in immediate danger, call 911.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Treatment-Resistant Depression is like, what's helped you, or ask the community a question.